The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 6, Issue 6, p. CD003101
Background Prostaglandins have been used for induction of labour since the 1960s. This is one of a series of reviews evaluating methods of induction of labour....
UNFAVORABLE CERVIX | Humans | DINOPROSTONE PESSARY | Administration, Intravaginal | RANDOMIZED-TRIAL | OUTPATIENT INDUCTION | Dinoprostone [administration & dosage] | EXPECTANT MANAGEMENT | Pregnancy | PREMATURE RUPTURE | PROLONGED PREGNANCY | MEDICINE, GENERAL & INTERNAL | Oxytocics [administration & dosage] | INTRAVAGINAL PROSTAGLANDIN-E2 | Labor, Induced [methods] | Dinoprost [administration & dosage] | DOUBLE-BLIND | Female | PRELABOR RUPTURE | Term Birth | Dinoprost - administration & dosage | Labor, Induced - methods | Oxytocics - administration & dosage | Dinoprostone - administration & dosage | Randomized Controlled Trials as Topic
UNFAVORABLE CERVIX | Humans | DINOPROSTONE PESSARY | Administration, Intravaginal | RANDOMIZED-TRIAL | OUTPATIENT INDUCTION | Dinoprostone [administration & dosage] | EXPECTANT MANAGEMENT | Pregnancy | PREMATURE RUPTURE | PROLONGED PREGNANCY | MEDICINE, GENERAL & INTERNAL | Oxytocics [administration & dosage] | INTRAVAGINAL PROSTAGLANDIN-E2 | Labor, Induced [methods] | Dinoprost [administration & dosage] | DOUBLE-BLIND | Female | PRELABOR RUPTURE | Term Birth | Dinoprost - administration & dosage | Labor, Induced - methods | Oxytocics - administration & dosage | Dinoprostone - administration & dosage | Randomized Controlled Trials as Topic
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 6, Issue 6, p. CD001338
Background Misoprostol is an orally active prostaglandin. In most countries misoprostol is not licensed for labour induction, but its use is common because it...
Administration, Oral | 100 MU-G | UNFAVORABLE CERVIX | Humans | RANDOMIZED CLINICAL-TRIAL | INTRACERVICAL DINOPROSTONE | Misoprostol [administration & dosage] | Randomized Controlled Trials as Topic | Pregnancy | PREMATURE RUPTURE | MEDICINE, GENERAL & INTERNAL | Oxytocics [administration & dosage] | Labor, Induced [methods] | VAGINAL MISOPROSTOL | DOUBLE-BLIND | ADMINISTERED MISOPROSTOL | Female | INTRAVENOUS OXYTOCIN | PRELABOR RUPTURE | Labor, Induced - methods | Misoprostol - administration & dosage | Oxytocics - administration & dosage | Cesarean Section - statistics & numerical data | Administration, Intravaginal | Dinoprostone - administration & dosage
Administration, Oral | 100 MU-G | UNFAVORABLE CERVIX | Humans | RANDOMIZED CLINICAL-TRIAL | INTRACERVICAL DINOPROSTONE | Misoprostol [administration & dosage] | Randomized Controlled Trials as Topic | Pregnancy | PREMATURE RUPTURE | MEDICINE, GENERAL & INTERNAL | Oxytocics [administration & dosage] | Labor, Induced [methods] | VAGINAL MISOPROSTOL | DOUBLE-BLIND | ADMINISTERED MISOPROSTOL | Female | INTRAVENOUS OXYTOCIN | PRELABOR RUPTURE | Labor, Induced - methods | Misoprostol - administration & dosage | Oxytocics - administration & dosage | Cesarean Section - statistics & numerical data | Administration, Intravaginal | Dinoprostone - administration & dosage
Journal Article
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2009, Issue 4, p. CD003101
Back ground Prostaglandins have been used for induction of labour since the 1960s. Initial work focused on prostaglandin F2a as prostaglandin E2 was considered...
Pregnancy | Oxytocics [administration & dosage] | Humans | Dinoprost [administration & dosage] | Labor, induced [methods] | Female | Dinoprostone [administration & dosage] | Term birth | Administration, intravaginal | UNFAVORABLE CERVIX | Administration, Intravaginal | RANDOMIZED-TRIAL | OUTPATIENT INDUCTION | EXPECTANT MANAGEMENT | PROLONGED PREGNANCY | PREMATURE RUPTURE | MEDICINE, GENERAL & INTERNAL | INTRAVAGINAL PROSTAGLANDIN-E2 | Labor, Induced [methods] | UTERINE ACTIVITY | DOUBLE-BLIND | PRELABOR RUPTURE | Dinoprost - administration & dosage | Labor, Induced - methods | Oxytocics - administration & dosage | Dinoprostone - administration & dosage | Term Birth
Pregnancy | Oxytocics [administration & dosage] | Humans | Dinoprost [administration & dosage] | Labor, induced [methods] | Female | Dinoprostone [administration & dosage] | Term birth | Administration, intravaginal | UNFAVORABLE CERVIX | Administration, Intravaginal | RANDOMIZED-TRIAL | OUTPATIENT INDUCTION | EXPECTANT MANAGEMENT | PROLONGED PREGNANCY | PREMATURE RUPTURE | MEDICINE, GENERAL & INTERNAL | INTRAVAGINAL PROSTAGLANDIN-E2 | Labor, Induced [methods] | UTERINE ACTIVITY | DOUBLE-BLIND | PRELABOR RUPTURE | Dinoprost - administration & dosage | Labor, Induced - methods | Oxytocics - administration & dosage | Dinoprostone - administration & dosage | Term Birth
Journal Article
Molecular Psychiatry, ISSN 1359-4184, 07/2006, Volume 11, Issue 7, pp. 680 - 684
Signs of an inflammatory process, in particular increased pro-inflammatory cytokines and increased levels of prostaglandine E-2 ( PGE(2)), have repeatedly been...
COX-2 inhibition | Inflammation | Psychoneuroimmunology | Major depression | Immunity | SYSTEM | COX-2 | PSYCHIATRY | BIOCHEMISTRY & MOLECULAR BIOLOGY | psychoneuroimmunology | SCHIZOPHRENIA | SICKNESS BEHAVIOR | SYMPTOMS | immunity | NEUROSCIENCES | INFLAMMATORY MARKERS | INTERFERON-ALPHA | PROSTAGLANDINS | inflammation | ROFECOXIB | major depression | BRAIN | Anti-Anxiety Agents - administration & dosage | Dinoprostone - analysis | Pyrazoles - therapeutic use | Adrenergic Uptake Inhibitors | Dinoprostone - biosynthesis | Humans | Middle Aged | Depressive Disorder - drug therapy | Male | Patient Dropouts | Lorazepam - therapeutic use | Inflammation - drug therapy | Cyclooxygenase 2 Inhibitors - therapeutic use | Adult | Female | Antidepressive Agents - pharmacology | Anti-Anxiety Agents - therapeutic use | Drug Therapy, Combination | Morpholines - therapeutic use | Pyrazoles - pharmacology | Severity of Illness Index | Cyclooxygenase 2 Inhibitors - pharmacology | Double-Blind Method | Cyclooxygenase 2 Inhibitors - administration & dosage | Morpholines - administration & dosage | Lorazepam - administration & dosage | Celecoxib | Sulfonamides - pharmacology | Antidepressive Agents - therapeutic use | Pilot Projects | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Depressive Disorder - physiopathology | Serotonin - metabolism | Interleukin-6 - biosynthesis | Antidepressive Agents - administration & dosage | Psychological Tests | Sulfonamides - administration & dosage | Inflammation - physiopathology
COX-2 inhibition | Inflammation | Psychoneuroimmunology | Major depression | Immunity | SYSTEM | COX-2 | PSYCHIATRY | BIOCHEMISTRY & MOLECULAR BIOLOGY | psychoneuroimmunology | SCHIZOPHRENIA | SICKNESS BEHAVIOR | SYMPTOMS | immunity | NEUROSCIENCES | INFLAMMATORY MARKERS | INTERFERON-ALPHA | PROSTAGLANDINS | inflammation | ROFECOXIB | major depression | BRAIN | Anti-Anxiety Agents - administration & dosage | Dinoprostone - analysis | Pyrazoles - therapeutic use | Adrenergic Uptake Inhibitors | Dinoprostone - biosynthesis | Humans | Middle Aged | Depressive Disorder - drug therapy | Male | Patient Dropouts | Lorazepam - therapeutic use | Inflammation - drug therapy | Cyclooxygenase 2 Inhibitors - therapeutic use | Adult | Female | Antidepressive Agents - pharmacology | Anti-Anxiety Agents - therapeutic use | Drug Therapy, Combination | Morpholines - therapeutic use | Pyrazoles - pharmacology | Severity of Illness Index | Cyclooxygenase 2 Inhibitors - pharmacology | Double-Blind Method | Cyclooxygenase 2 Inhibitors - administration & dosage | Morpholines - administration & dosage | Lorazepam - administration & dosage | Celecoxib | Sulfonamides - pharmacology | Antidepressive Agents - therapeutic use | Pilot Projects | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Depressive Disorder - physiopathology | Serotonin - metabolism | Interleukin-6 - biosynthesis | Antidepressive Agents - administration & dosage | Psychological Tests | Sulfonamides - administration & dosage | Inflammation - physiopathology
Journal Article
Pain, ISSN 0304-3959, 11/2015, Volume 156, Issue 11, pp. 2326 - 2336
High-altitude, or hypobaric hypoxia, headache has recently emerged as an interesting model to study placebo and nocebo responses, and particularly their...
Heart rate | Headache | High altitude | Placebo | Fatigue | Prostaglandin E | Oxygen saturation | NOCEBO | PLACEBO ANALGESIA | Prostaglandin E-2 | HYPOXIA | NEUROSCIENCES | MIDDLE CEREBRAL-ARTERIES | CLINICAL NEUROLOGY | SKELETAL-MUSCLE | PAIN | PROSTAGLANDINS | ENDOTHELIUM | CLUSTER HEADACHE | ANESTHESIOLOGY | ACUTE MOUNTAIN-SICKNESS | Headache - etiology | Double-Blind Method | Humans | Male | Treatment Outcome | Saliva - chemistry | Healthy Volunteers | Dinoprostone - metabolism | Young Adult | Hyperbaric Oxygenation - methods | Statistics, Nonparametric | Electrocardiography | Adult | Female | Headache - therapy | Altitude
Heart rate | Headache | High altitude | Placebo | Fatigue | Prostaglandin E | Oxygen saturation | NOCEBO | PLACEBO ANALGESIA | Prostaglandin E-2 | HYPOXIA | NEUROSCIENCES | MIDDLE CEREBRAL-ARTERIES | CLINICAL NEUROLOGY | SKELETAL-MUSCLE | PAIN | PROSTAGLANDINS | ENDOTHELIUM | CLUSTER HEADACHE | ANESTHESIOLOGY | ACUTE MOUNTAIN-SICKNESS | Headache - etiology | Double-Blind Method | Humans | Male | Treatment Outcome | Saliva - chemistry | Healthy Volunteers | Dinoprostone - metabolism | Young Adult | Hyperbaric Oxygenation - methods | Statistics, Nonparametric | Electrocardiography | Adult | Female | Headache - therapy | Altitude
Journal Article
Acta Anaesthesiologica Scandinavica, ISSN 0001-5172, 03/2013, Volume 57, Issue 3, pp. 395 - 397
Sulprostone, a synthetic prostaglandin analogue with potent uterotonic action, has been shown to have a low complication rate in a large series. We present a...
ANESTHESIOLOGY | POSTPARTUM HEMORRHAGE | MISOPROSTOL | ANALOG | RECEPTORS | Postoperative Hemorrhage | Anesthesia, General | Humans | Advanced Cardiac Life Support | Dinoprostone - adverse effects | Anesthesia, Spinal | Pregnancy | Cardiopulmonary Resuscitation | Cesarean Section | Glasgow Coma Scale | Dinoprostone - analogs & derivatives | Adult | Female | Heart Arrest - chemically induced | Anesthesia, Obstetrical | Heart Arrest - therapy | Cardiac arrest
ANESTHESIOLOGY | POSTPARTUM HEMORRHAGE | MISOPROSTOL | ANALOG | RECEPTORS | Postoperative Hemorrhage | Anesthesia, General | Humans | Advanced Cardiac Life Support | Dinoprostone - adverse effects | Anesthesia, Spinal | Pregnancy | Cardiopulmonary Resuscitation | Cesarean Section | Glasgow Coma Scale | Dinoprostone - analogs & derivatives | Adult | Female | Heart Arrest - chemically induced | Anesthesia, Obstetrical | Heart Arrest - therapy | Cardiac arrest
Journal Article
Depression and Anxiety, ISSN 1091-4269, 07/2009, Volume 26, Issue 7, pp. 607 - 611
Background: The pathophysiology of depression is associated with the hyperactivity of immune inflammatory responses. Cyclooxygenase‐2 inhibitors such as...
clinical trial | fluoxetine | COX‐2 inhibitor | major depression | Clinical trial | COX-2 inhibitor | Fluoxetine | Major depression | DRUG | CYTOKINES | PSYCHIATRY | SCHIZOPHRENIA | DISORDERS | PSYCHOLOGY, CLINICAL | PSYCHOLOGY | Pyrazoles - therapeutic use | Interleukin-6 - antagonists & inhibitors | Prospective Studies | Dinoprostone - biosynthesis | Humans | Middle Aged | Male | Young Adult | Cyclooxygenase 2 Inhibitors - therapeutic use | Adult | Female | Surveys and Questionnaires | Fluoxetine - therapeutic use | Drug Therapy, Combination | Depressive Disorder, Major - drug therapy | Pyrazoles - pharmacology | Severity of Illness Index | Depressive Disorder, Major - physiopathology | Diagnostic and Statistical Manual of Mental Disorders | Cyclooxygenase 2 Inhibitors - pharmacology | Double-Blind Method | Drug Administration Schedule | Cyclooxygenase 2 Inhibitors - administration & dosage | Serotonin Uptake Inhibitors - therapeutic use | Celecoxib | Sulfonamides - pharmacology | Pyrazoles - administration & dosage | Serotonin Uptake Inhibitors - administration & dosage | Sulfonamides - therapeutic use | Fluoxetine - administration & dosage | Interleukin-6 - biosynthesis | Depressive Disorder, Major - diagnosis | Dinoprostone - antagonists & inhibitors | Sulfonamides - administration & dosage
clinical trial | fluoxetine | COX‐2 inhibitor | major depression | Clinical trial | COX-2 inhibitor | Fluoxetine | Major depression | DRUG | CYTOKINES | PSYCHIATRY | SCHIZOPHRENIA | DISORDERS | PSYCHOLOGY, CLINICAL | PSYCHOLOGY | Pyrazoles - therapeutic use | Interleukin-6 - antagonists & inhibitors | Prospective Studies | Dinoprostone - biosynthesis | Humans | Middle Aged | Male | Young Adult | Cyclooxygenase 2 Inhibitors - therapeutic use | Adult | Female | Surveys and Questionnaires | Fluoxetine - therapeutic use | Drug Therapy, Combination | Depressive Disorder, Major - drug therapy | Pyrazoles - pharmacology | Severity of Illness Index | Depressive Disorder, Major - physiopathology | Diagnostic and Statistical Manual of Mental Disorders | Cyclooxygenase 2 Inhibitors - pharmacology | Double-Blind Method | Drug Administration Schedule | Cyclooxygenase 2 Inhibitors - administration & dosage | Serotonin Uptake Inhibitors - therapeutic use | Celecoxib | Sulfonamides - pharmacology | Pyrazoles - administration & dosage | Serotonin Uptake Inhibitors - administration & dosage | Sulfonamides - therapeutic use | Fluoxetine - administration & dosage | Interleukin-6 - biosynthesis | Depressive Disorder, Major - diagnosis | Dinoprostone - antagonists & inhibitors | Sulfonamides - administration & dosage
Journal Article
Journal of Urology, The, ISSN 0022-5347, 2007, Volume 178, Issue 5, pp. 2208 - 2212
Purpose Antimuscarinic drugs increase bladder capacity without prominent side effects such as urinary retention even when administered to patients with mild to...
Urology | rats, Sprague-Dawley | muscarinic antagonists | prostaglandins E | urethra | bladder | omega-Conotoxins - administration & dosage | Adrenergic alpha-Antagonists - administration & dosage | Verapamil - administration & dosage | Dinoprostone - administration & dosage | Urinary Bladder, Overactive - drug therapy | Urinary Bladder, Overactive - physiopathology | Oxytocics - administration & dosage | Female | Benzilates - administration & dosage | Urethra - drug effects | Disease Models, Animal | Rats | Treatment Outcome | Pressure | Rats, Sprague-Dawley | Urethra - physiopathology | Cholinergic Antagonists - administration & dosage | Muscarinic Antagonists - administration & dosage | Animals | Muscle Contraction - drug effects | Calcium Channel Blockers - administration & dosage | Urinary Bladder - physiopathology | Urinary Bladder - drug effects | Administration, Intravesical | Atropine - administration & dosage | Administration, Topical | Sulfonamides - administration & dosage | Injections, Intra-Arterial
Urology | rats, Sprague-Dawley | muscarinic antagonists | prostaglandins E | urethra | bladder | omega-Conotoxins - administration & dosage | Adrenergic alpha-Antagonists - administration & dosage | Verapamil - administration & dosage | Dinoprostone - administration & dosage | Urinary Bladder, Overactive - drug therapy | Urinary Bladder, Overactive - physiopathology | Oxytocics - administration & dosage | Female | Benzilates - administration & dosage | Urethra - drug effects | Disease Models, Animal | Rats | Treatment Outcome | Pressure | Rats, Sprague-Dawley | Urethra - physiopathology | Cholinergic Antagonists - administration & dosage | Muscarinic Antagonists - administration & dosage | Animals | Muscle Contraction - drug effects | Calcium Channel Blockers - administration & dosage | Urinary Bladder - physiopathology | Urinary Bladder - drug effects | Administration, Intravesical | Atropine - administration & dosage | Administration, Topical | Sulfonamides - administration & dosage | Injections, Intra-Arterial
Journal Article
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2009, Issue 4, p. CD003246
Background Oxytocin is the commonest induction agent used worldwide. It has been used alone, in combination with amniotomy or following cervical ripening with...
Pregnancy | Oxytocics [administration & dosage] | Humans | Labor, induced | Oxytocin [administration & dosage] | Female | Randomize d controlled trials as topic | Injections, intravenous | Cervical ripening | Dinoprostone [administration & dosage] | Injections, Intravenous | LOW-DOSE OXYTOCIN | UNFAVORABLE CERVIX | RANDOMIZED-TRIAL | Clinical Trials as Topic | EXPECTANT MANAGEMENT | VAGINAL PROSTAGLANDIN-E2 PESSARIES | Cervical Ripening | Labor, Induced | PREMATURE RUPTURE | MEDICINE, GENERAL & INTERNAL | PULSATILE OXYTOCIN | UTERINE ACTIVITY | PRELABOR RUPTURE | EPIDURAL ANALGESIA | Oxytocin - administration & dosage | Oxytocics - administration & dosage | Dinoprostone - administration & dosage | Randomized Controlled Trials as Topic
Pregnancy | Oxytocics [administration & dosage] | Humans | Labor, induced | Oxytocin [administration & dosage] | Female | Randomize d controlled trials as topic | Injections, intravenous | Cervical ripening | Dinoprostone [administration & dosage] | Injections, Intravenous | LOW-DOSE OXYTOCIN | UNFAVORABLE CERVIX | RANDOMIZED-TRIAL | Clinical Trials as Topic | EXPECTANT MANAGEMENT | VAGINAL PROSTAGLANDIN-E2 PESSARIES | Cervical Ripening | Labor, Induced | PREMATURE RUPTURE | MEDICINE, GENERAL & INTERNAL | PULSATILE OXYTOCIN | UTERINE ACTIVITY | PRELABOR RUPTURE | EPIDURAL ANALGESIA | Oxytocin - administration & dosage | Oxytocics - administration & dosage | Dinoprostone - administration & dosage | Randomized Controlled Trials as Topic
Journal Article
Carbohydrate Polymers, ISSN 0144-8617, 10/2018, Volume 198, pp. 418 - 425
This study aimed to develop a novel sustained release system for mesalazine (MSZ) by preparing hydroxypropyl-β-cyclodextrin (HP-β-CD) inclusion complex loaded...
Nanoparticles | Sustained release | Hydroxypropyl-β-cyclodextrin | Chitosan | Mesalazine | Anti-inflammatory | DRUG | POLYMER SCIENCE | COMPLEXES | ENCAPSULATION | CHEMISTRY, ORGANIC | Hydroxypropyl-beta-cyclodextrin | CHITOSAN NANOPARTICLES | SOLUBILITY | CHEMISTRY, APPLIED | TARGETED DELIVERY | Cell Survival - drug effects | Nanoparticles - chemistry | Humans | Chitosan - administration & dosage | Solubility | Drug Carriers - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Delayed-Action Preparations - chemistry | 2-Hydroxypropyl-beta-cyclodextrin - administration & dosage | Drug Carriers - chemistry | Delayed-Action Preparations - administration & dosage | Dinoprostone - metabolism | HT29 Cells | Mesalamine - chemistry | Chitosan - chemistry | 2-Hydroxypropyl-beta-cyclodextrin - chemistry | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Drug Liberation | Nanoparticles - administration & dosage | Interleukin-8 - metabolism | Nitric Oxide - metabolism | Mesalamine - administration & dosage
Nanoparticles | Sustained release | Hydroxypropyl-β-cyclodextrin | Chitosan | Mesalazine | Anti-inflammatory | DRUG | POLYMER SCIENCE | COMPLEXES | ENCAPSULATION | CHEMISTRY, ORGANIC | Hydroxypropyl-beta-cyclodextrin | CHITOSAN NANOPARTICLES | SOLUBILITY | CHEMISTRY, APPLIED | TARGETED DELIVERY | Cell Survival - drug effects | Nanoparticles - chemistry | Humans | Chitosan - administration & dosage | Solubility | Drug Carriers - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Delayed-Action Preparations - chemistry | 2-Hydroxypropyl-beta-cyclodextrin - administration & dosage | Drug Carriers - chemistry | Delayed-Action Preparations - administration & dosage | Dinoprostone - metabolism | HT29 Cells | Mesalamine - chemistry | Chitosan - chemistry | 2-Hydroxypropyl-beta-cyclodextrin - chemistry | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Drug Liberation | Nanoparticles - administration & dosage | Interleukin-8 - metabolism | Nitric Oxide - metabolism | Mesalamine - administration & dosage
Journal Article
Carcinogenesis, ISSN 0143-3334, 05/2003, Volume 24, Issue 5, pp. 985 - 990
Although an accumulating body of evidence indicates that levels of prostaglandin E(2) (PGE(2)) in human and rodent colon cancers are higher than those in...
Intestinal Mucosa - metabolism | Apoptosis - drug effects | Rats, Inbred F344 | Colon - drug effects | Injections, Intraperitoneal | Rats | Bromodeoxyuridine | Colonic Neoplasms - chemically induced | Male | DNA Primers - chemistry | Dinoprostone - blood | Reverse Transcriptase Polymerase Chain Reaction | Adenocarcinoma - drug therapy | Azoxymethane - toxicity | Colon - metabolism | Colonic Neoplasms - metabolism | Disease Progression | Carcinogens - toxicity | Dinoprostone - administration & dosage | Incidence | Animals | Colonic Neoplasms - pathology | Receptors, Prostaglandin E - metabolism
Intestinal Mucosa - metabolism | Apoptosis - drug effects | Rats, Inbred F344 | Colon - drug effects | Injections, Intraperitoneal | Rats | Bromodeoxyuridine | Colonic Neoplasms - chemically induced | Male | DNA Primers - chemistry | Dinoprostone - blood | Reverse Transcriptase Polymerase Chain Reaction | Adenocarcinoma - drug therapy | Azoxymethane - toxicity | Colon - metabolism | Colonic Neoplasms - metabolism | Disease Progression | Carcinogens - toxicity | Dinoprostone - administration & dosage | Incidence | Animals | Colonic Neoplasms - pathology | Receptors, Prostaglandin E - metabolism
Journal Article